Sanders Presses For Lower Semaglutide Drug Prices, Novo Nordisk Responds

By Maaisha Osman / April 15, 2024 at 7:21 PM
Senate health committee Chair Bernie Sanders (I-VT) is pressing pharmaceutical company Novo Nordisk to lower prices of its blockbuster semaglutide drugs Ozempic and Wegovy, claiming Medicare will go bankrupt if the prices of the diabetes and obesity drugs are not lowered. Novo Nordisk tells Inside Health Policy that the public debate doesn’t consider the “complex reality” of developing these medications, but it remains committed to making these medications affordable to patients. Calling for policy makers and others to get...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.